Abstract: A bacteriolytic enzyme complex obtained from a bacterial culture of Nocardiopsis dassonvillei strains, e.g., isolates G102-3 (NRRL 18349), G119-6 (NRRL 18350), and D38-3 (NRRL 18364).The enzyme complex may be produced by cultivating the microorganism in an aqueous medium containing maltodextrin and soybean meal, after which the lytic enzyme complex may be recovered from the fermentation broth.This bacteriolytic enzyme complex is useful as a detergent additive.

Abstract: Chimeric alpha-amylases are disclosed of the formulaQ--R--Lin which Q is a N-terminal polypeptide residue of from 55 to 60 amino acid residues which is at least 75 percent homologous to the 55 N-terminal amino acid residues in the Bacillus amyloliquefaciens alpha-amylase as described in Takkinen et al., J. Biol. Chem. 258 (1983) 1007-1013,R is a polypeptide residue of the general formula ##STR1## L comprises a C-terminal polypeptide of from 390 to 400 amino acid residues which is at least 75 percent holologous to the 395 C-terminal amino acid residues in the Bacillus licheniformis 584 (ATCC 27811) alpha-amylase.

Abstract: Rhizobia transformants that nodulate and fix nitrogen in non-legumes. The nodulated non-legume plants can be grown without nitrogenous fertilizer and have at least the same or higher protein content, dry matter content and nitrogen content than their non-nodulated counterparts which are fertilized by the addition of nitrogenous fertilizer. The straw remaining after harvesting the nodulated non-legumes is also high in protein content.

Abstract: The concentration of glycated hemoglobin, HbA.sub.1c, in hemoglobin from diabetic patients is regarded as a useful means of assessing the adequacy of diabetes control. This invention comprises a monoclonal antibody which, due to its specific binding of HbA.sub.1c, can be used for the determination of HbA.sub.1c in the absence of prior denaturation, in blood samples by such analytical methods as radioimmuno assay or enzyme-linked immunosorbent assay. The invention also comprises hybridoma cell lines which produce monoclonal antibodies of the invention.

Abstract: A method of producing algal cell wall degrading enzyme by cultivating a thermophilic, bacterial strain of an atypical Bacillus stearothermophilus e.g., W36-7-4 (NRRL B-18394) which produces the alginate lyase in a cultivation medium containing sodium alginate and tryptone, then allowing growth to take place to accumulate alginate lyase, and then recovering the enzyme from the fermentation broth. The novel alginate lyase of this invention is useful as a treatment agent for water cooling systems.

Abstract: Human conglutinin, polyclonal, and monoclonal antibodies raised against human conglutinin, and their uses in therapy and diagnosis are described.Human conglutinin was obtained from human plasma by affinity chromatography with anti-bovine conglutinin antibody, has a relative molecular weight of 330 and 40 K unreduced and 66 K reduced as measured by SDS-PAGE, shows calcium-dependent and sugar inhibitable binding to complement-reacted immune complexes and zymosan, and immunological cross-reaction with anti-bovine conglutinin antibody.

Abstract: A novel cyanide converting enzyme, a "cyanidase" is described.The enzyme is extremely efficient in reducing substantial concentrations of cyanide to very low levels in a broad pH, and temperature range, and in the presence of organics and metal ions.

Abstract: Insulin preparations with improved properties for parenteral administration can be prepared at pH values of about 3 to 8.5 by presence of magnesium ions in concentration of about 0.005 to 0.5M, a preferred range is 0.02M to 0.5M.

Abstract: The present invention relates to a disposable syringe the barrel (4) of which is provided with a blob (6) of a cured adhesive substance on the barrel that prevents the piston (5) from being pulled out of the open rear end (8) of the barrel (4), for example when operated by an unexperienced person.

Abstract: The granulate detergent enzyme product comprises a core of a microbial enzyme containing material with an enteric coating. Due to the coating the enzymatic stability is enhanced, in the presence of other detergent components, espacially strong bleaching agents. The coating is usually carried out in a fluid bed. Also coatings with antioxidants and acid coatings enhance the enzymatic stability.

Abstract: A novel beta amylase enzyme product with improved thermostability and acid-stability is provided. The novel enzyme can be produced by cultivating a newly discovered microorganism Bacillus sp. (21-51) belonging to the Bacillus acidopullulyticus complex and may be used alone or in combination with a variety of conventional debanching enzymes in the production of high maltose syrups.

Abstract: An enteral diet composition which comprises a balanced diet aqueous medium mixture of fat, carbohydrate, and dietary nitrogen compounds characterized by a total energy content of at least about 0.68 kcal/ml, an osmolality of below about 350 milli-osmol and a pH lower than about 4.5. The dietary nitrogen compounds are at least about 95% soluble in the aqueous medium and are free from bitterness in the composition. At least about 50% of the dietary nitrogen compounds is derived from vegetable protein source(s).The enteral diet product exhibits a combination of advantageous characteristics, i.e., good microbiological stability, good physical stability of the emulsion, low osmolality, satisfactory organoleptic properties, and satisfactory nutritional and handling properties.

Abstract: A mixed enzyme product comprising a mixture of the alpha-amylase from Bacillus licheniformis and the alpha-amylase from B. stearothermophilus, said mixture containing from 10%-90%, preferably 25%-90%, more preferably 25%-75% by activity as NU/g DS of the Bacillus licheniformis enzyme and is usable with advantage for liquefaction of starch or starchy grains.

Abstract: Compounds of the Formula I ##STR1## wherein R.sup.1 represents phenyl, or phenyl substituted by one, or more substituents selected from the group consisting of halogen, C.sub.1-7 -alkyl, and C.sub.1-7 -alkoxy, R.sup.2 represents furanyl, thienyl, pyridyl or pyrrolyl ortho substituted with C.sub.1-7 -alkyl or halogen and wherein R.sup.3 represents 3-carboxypiperidin-1-yl, 3-carboxy-1,2,5,6-tetrahydropyridin-1-yl or 3-carboxymethyl-pyrrolidin-1-yl, pharmaceutical compositions containing effective amounts of a compound of formula I and treatment of central nervous system ailments by administering a compound of formula I.

Abstract: Combinations of alkaline Bacillus protease with alkaline fungal or actinomycete protease show improved detergency. Proteases obtainable from Fusarium sp. or Paecilomyces sp. (fungal) and Nocardiopsis sp. (actinomycete) are preferred.

Abstract: A method for stabilization of extra-chromosomal elements in bacteria during cultivation which comprises transformation of a host bacterium having a defect in a chromosomal gene needed for the synthesis or maintenance of the cell envelope with an extra-chromosomal element capable of complementing the chromosomal gene defect of the host bacterium, the extra-chromosomal element also including an expressible DNA-sequence coding for a desired product.

Abstract: Human insulin precursors containing the peptide chain B(1-29)-A(1-21) of human insulin and derivatives thereof with a bridging chain connecting the carboxyl terminus of the B(1-29)-chain with the amino terminus of the A(1-21)-chain are prepared by culturing a yeast host transformed with a replicable expression vehicle capable of expressing a DNA-sequence encoding the insulin precursor. The bridging chain is preferably relatively short and contains preferably from 2 to 8 amino acid residues. The bridging chain must not contain two adjacent basic amino acid residues (Lys or Arg) and has one Lys or Arg connected to the amino terminus of the A(1-21)-chain. Human insulin is prepared from the insulin precursors by in vitro conversion.

Abstract: Human conglutinin, polyclonal, and monoclonal antibodies raised against human conglutinin, and their uses in therapy and diagnosis are described.Human conglutinin was obtained from human plasma by affinity chromatography with anti-bovine conglutinin antibody, has a relative molecular weight of 330 and 40 K unreduced and 66 K reduced as measured by SDS-PAGE, shows calcium-dependent and sugar inhibitable binding to complement-reacted immune complexes and zymosan, and immunological cross-reaction with anti-bovine conglutinin antibody.

Abstract: The method for production of an upgraded coconut product comprises the steps of: enzymatically treating an aqueous suspension of particles of coconut meat, which may be purified, with a cell wall degrading enzyme and a galactomannase, all essentially free from lipases, and separating a sludge phase. By means of this method a higher yield of directly recoverable clear coconut oil can be obtained in comparison to the yield of directly recoverably clear coconut oil produced by known methods for aqueous coconut oil extraction.

Abstract: Immobilized biologically active material in particle form is prepared by cross-linking with glutaraldehyde and polyazetidine. An aqueous dispersion or solution of biologically active material is partially cross-linked with glutaraldehyde, a wet pasty mass is recovered by dewatering and the mass is sub-divided into discrete particles. A polyazetidine prepolymer is added before, at the beginning or subsequent to partially cross-linking but prior to subdividing the pasty mass into particles, and the prepolymer is allowed to cross-link.